Adrenocorticotropin hormone (ACTH) and adrenal steroids may influence trophic processes operative in neuronal plasticity. Because nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) participate in neuronal trophism, we have investigated whether adrenal steroids induce the expression of these two trophic factors in the rat brain. The systemic administration of dexamethasone (DEX) elicited a rapid (within 3 hr) and sustained accumulation of bFGF and NGF mRNA in the cerebral cortex and hippocampus.
The nervous and endocrine systems are engaged in an intense biological dialogue and, by sharing many chemical signals, interact at several levels to shield the organism against noxious agents or hostile environmental conditions. The role of adrenal steroids in the ncuroendocrinc regulation of hypothalamic-pituitary-adrenocortical system in response to stress is well documented. The brain expresses both mineralocorticoid and glucocorticoid receptors and is, among other tissues, a target for adrenal corticosteroids (McEwen et al., 1986) . Indeed, adrenal secreted steroids appear to regulate memory consolidation and learning, and influence mood and complex behavioral interactions (McEwen et al., 1986) . A great deal of research has focused on the hypothesis that adrenal steroids or adrcnocorticotropic hormone (ACTH) might be important regulators of trophic processes operative in synaptic plasticity. During development, glucocorticoids modulate cell growth and differentiation and inhibit cell proliferation (Meyer, 1983 , and ACTH increases nerve terminal branching (Strand et al., 1989) typical responses that are belicvcd to bc associated with synaptic plasticity. In the mature brain, corticostcronc rcduccs both cell death of hippocampal granule cells (Sloviter et al., 1989) and morphological changes of the dentate gyrus (Gould et al., 1990) of neurons require a continuous influx of adrenal steroids to maintain structural integrity and enhance survival. Many of the primary effects of adrenal steroids involve transcriptional regulation of a subset of genes in specific cell types, including neurotransmitters, receptors, and neuropeptides (Harlan, 1988) . However, little is known about the mechanisms of these effects and the basis for a "neurotrophic" activity of the adrenal corticosteroids. Given the well established role of neurotrophic factors and the complexity of molecular events influencing synaptic plasticity, it has been suggested that adrenal steroids may exert trophic activity by inducing the synthesis and availability of trophic factors in the developing as well as mature CNS (Aloe, 1989; Mocchetti, 1991) . Indeed, several lines of independent evidence have demonstrated that the synthetic glucocorticoid dexamethasonc (DEX) modulates the expression of nerve growth factor (NGF) in selected brain regions (Fabrazzo et al., 1991; Barbany and Pcrsson, 1992; Saporito et al., 1994) suggesting that the induction of trophic factor synthesis represents a link by which the adrenal cortical system can exert trophic action in the mature CNS.
Relatively little is known about the contribution of adrenal corticosteroids and the pituitary ACTH in the induction of NGF. Moreover, it is still unclear what role the hypothalamic-pituitaryadrenal axis has in the regulation of basic fibroblast growth factor (bFGF), a prototype member of the heparin trophic factor family (Burgess and Maciag, 1989) , which is believed to play a role in CNS plasticity (Anderson et al., 1988; Otto and Unsicker, 1990; Follesa et al., 1994) . We report that synthetic and naturally occurring adrenal steroids induce a temporal and anatomical induction of bFGF expression distinct from that of NGF. This proccdurc generated a '*P-labclcd 524 base probe, which includes the 477 bases 01 bFGF cRNA and 47 bases of the plasmid polylinkcr region (Follcsa and Mocchetti, 1993; Follcsa et al., 1994) . The cRNA for acidic FGF (aFGF) was generated from HBGF-I plasmid (Goodrich ct al., 1989) (a gift from Dr. S. Goodrich, Alton Jones Cell Science, Lake Placid, NY) as described previously (Follesa ct al., 1994) . The cRNA for cyclophilin was in vitro transcribed with SP6 polymerase from EcoRI linearized plasmid plG15 (Colangelo et al., 1994; Follcsa ct al., 1994; Hayes et al., 1995) . This probe was used as a standard control to monitor artifacts attributable to extraction of RNA.
MATERIALS AND METHODS
RNA was extracted from brain tissues (Chomczynski and Sacchi, 1987 Mocchetti, 1993; Follesa et al., 1994) .
In situ hyhridiza~ion. In sirn hybridization was performed as described previously (Gall and Isackson, 1989; Isackson et al., 1991; Hayes et al., 1995 Fractions of the supernatant (400 ~1) were added to a tube containing 50 ~1 of heparin-Sepharose CL-6B slurry (Pharmacia, Piscataway, NJ) (100 mg swelled in I ml of TE containing 0.6 M NaCI) and shaken overnight at 4°C. The heparin-Sepharose was precipitated at 13,000 x g, and the pellet was washed three times with 0.6 M NaCI, 10 mM Tris HCI, pH 7.4. Final pellets were boiled in loading butfer (2% SDS, 100 PM ulation of trophic factor expression in the brain, rats were injected with the synthetic glucocorticoid DEX. Time-course studies revealed that in the cerebral cortex, DEX (0.5 mgikg, s.c.) failed to change the levels of both mRNAs at 1 hr, but elicited a twofold increase in bFGF and NGF mRNA content 3 hr after the injection (Fig. 1A) . The profile of bFGF mRNA induction was slightly different from that of NGF because accumulation of bFGF mRNA reached peak values at 6 hr ( Fig. lA) , whereas NGF mRNA levels started to decline by 6 hr. The content of both mRNA species gradually returned to control levels within 24 hr postadministration of DEX. In contrast, NGF and bFGF mRNA levels remained constant over time within the control groups, fluctuating no more than 10%. Moreover, the content of aFGF mRNA remained unchanged over time in the DEX-treated cohort (data not shown), indicating specificity in the induction of bFGF mRNA.
Time-course studies were also performed to characterize the temporal pattern of NGF and bFGF mRNA in the hippocampus after systemic DEX administration.
By 3 hr, DEX elicited a significant increase in bFGF and NGF mRNA (Fig. 1B) . By 6 hr, however, the content of NGF mRNA started to decline, whereas that of bFGF reached peak induction (Fig. 1B) . bFGF mRNA remained elevated at 10 hr (twofold) and returned to control values by 36 hr (Fig. 1B) .
Dose-response studies The dose of DEX (0.5 mg/kg, s.c.) used to increase the content of NGF and bFGF mRNA roughly approximates plasma glucocorticoid levels occurring during intense stress (Sapolsky et al., 1986) . Dose-response studies were performed to determine whether lower or higher concentrations of DEX can elicit a comparable accumulation of trophic factor mRNA. In the cerebral cortex, by 3 hr the dose of 0.1 mgikg (s.c.) elicited a modest but significant increase in the levels of both mRNAs (Fig. 2) . The peak effect was observed at a dose of 5 mgikg (s.c.). The levels of bFGF and NGF mRNA failed to significantly differ at doses of 0.5, 1, and 5 mg/kg (Fig. 2) . A similar concentration-dependent increase in both mRNAs was observed in the hippocampus (data not shown).
Anatomical specificity of bFGF and NGF mRNA induction after DEX We examined the levels of NGF and bFGF mRNA in additional brain regions at various times after DEX (0.5 mgikg). The synthetic glucocorticoid elicited a time-dependent increase in bFGF mRNA in the hypothalamus, cerebellum, and striatum similar to that observed in the cerebral cortex. Thus, the DEX-induced increase in bFGF mRNA peaked at 6 hr ( Fig. 3) and declined by 24 hr (data not shown). In these brain regions, NGF mRNA failed to change at any time (data not shown) consistent with previous findings (Fabrazzo et al., 1991) .
We used in situ hybridization to localize NGF and bFGF mRNA induction in specific areas of the brain in which we may have failed to detect changes because of induction restricted to a particular Time after injection (hr) Figure 3 . Regional increase in bFGF mRNA after DEX. Rats received DEX (0.5 mgikg, s.c.) and were killed at the indicated time. Hypothalamus, cerebellum, and striatum were dissected. Data are the mean t-SEM of three separate experiments (n = g/group). *p < 0.01 (ANOVA and Dunnett's test). No changes were observed in the levels of NGF mRNA between control and DEX-treated rats in these areas.
subset of cell layers. In control rats, NGF mRNA was relatively abundant in hippocampus dentate gyrus and in the superficial layers of the cortex (Fig. 4) , similar to previous observations (Gall and Isackson, 1989; Gall et al., 1991; Isackson et al., 1991; Hayes et al., 1995) . In brain sections of rats killed 3 hr after DEX injection, antisense NGF cRNA probe hybridization revealed that NGF mRNA levels were increased in the superficial layers of the cortex and in particular in the cingulate and piriform cortex (Fig. 4 and Table l), supporting the data obtained with RNase protection assay. In the hippocampus, NGF mRNA levels remained unchanged in the pyramidal cell layers, but increased in the dentate granule cell layers of the same brains (Fig. 4 and Table 1 ). Brain sections of control rats, processed with bFGF cRNA, showed the typical bFGF hybridization scattered throughout the brain, as shown previously (Emoto et al., 1989; Gall et al., 1994; Hayes et al., 1995) , which suggests expression of bFGF in glial cells. bFGF hybridization was also localized in the CA2 layer of the hippocampus, where bFGF mRNA has been found to be expressed in neurons (Woodward et al., 1992) . DEX-treated rats showed elevated levels of bFGF mRNA expression evenly distributed over all cortical regions (Fig. 4) . In the hippocampus, DEX increased bFGF mRNA expression in glial cells within the stratum lacunosum moleculare (Fig. 4) . In the CA2 region, we failed to observe increased hybridization after DEX (Table 1) . Tissue processed with the sense bFGF cRNA probe showed no labeling in any of the regions where specific bFGF hybridization was described above (Fig. 4) , confirming the specificity of the signal obtained with antisense bFGF cRNA probe.
Induction of bFGF protein after DEX DEX has been shown to increase NGF protein in rat cerebral cortex (Fabrazzo et al., 1991) and in the hippocampus (Saporito et al., 1994) . To determine whether DEX increases bFGF protein, hippocampal extracts of control and experimental animals were analyzed by Western blot using DE6, a bFGF monoclonal antibody that does not show cross reactivity with aFGF (Reilly et al., 1989) (Fig. 5A, lane 5) . DE6 recognizes two characteristic forms of the recombinant human bFGF; a dominant fragment of -18 kDa, and a higher molecular weight (-36 kDa) immunoreactive bFGF form (Fig. 5A, lanes 2-4) , which may represent the nonreducible dimer. In tissue extracts (heparin-bound material), DE6 recognizes, in addition to the 18 kDa band (light awow), two higher molecular forms of bFGF (22-24 kDa) (Fig. 5B, awowheud) , most likely originating from a 5' CUG codons as demonstrated by other investigators (Florkiewicz and Sommer, 1989; Woodward et al., 1992) . In addition, the antibody recognizes some higher molecular weight forms, which might represent the nonreducible dimer and related proteolytic fragments. Although the biochemical nature of these putative high molecular weight forms is still under investigation, they are likely to be derivatives of bFGF, because an aFGF antibody failed to immunoprecipitate these fragments (Koshinaga et al., 1993) .
Analysis of tissue extracts from hippocampus of rats treated with vehicle or DEX and killed at different times revealed that DEX failed to change bFGF proteins by 3 hr (data not shown). By 6 hr, the glucocorticoid elicited a twofold increase (190% + 20) in the two major (22 and 24 kDa) bFGF immunoreactive species (Fig. 5B, lanes 5-8) . The content of bFGF proteins decreased almost to control values by 24 hr (data not shown).
Induction of NGF and bFGF mRNA by ACTH ACTH regulates the synthesis and release of adrenal corticosteroids (Axelrod and Reisine, 1984) . We examined whether ACTH could evoke an induction in NGF and bFGF mRNA similar to that elicited by DEX. The administration of ACTH (15 U/Kg, s.c.) increased both mRNA levels in the cerebral cortex (Fig. 6A) and hippocampus (Fig. 6B) . To further test the role of ACTH and adrenal corticosteroids in the regulation of bFGF and NGF mRNA expression, ACTH or DEX was injected in adrenalectomized rats. In these animals, ACTH failed to change NGF and bFGF mRNA levels in both regions (Fig. 6A, B) . However, adrenalectomy did not prevent the DEX-mediated accumulation of NGF and bFGF mRNA in both the cerebral cortex and hippocampus (Fig. 6A, B) , supporting the important role of adrenal corticosteroids in the ACTH-mediated regulation of NGF and bFGF expression.
Aldosterone and cotticosterone change NGF and bFGF mRNAs We next used corticosterone (CORT) and aldosterone (ALDO) to examine the role of blood-borne steroids in the induction of NGF and bFGF mRNA expression. By 3 hr, both CORT (10 mg/kg, s.c.) and ALDO (10 mg/kg, s.c.) increased the content of bFGF mRNA in the cerebral cortex to a similar extent (Fig. 7A) . However, the CORT-mediated increase in NGF mRNA levels was significantly different from that evoked by ALDO (Fig. 7A) . Dose-response studies revealed that both steroids failed to change NGF and bFGF mRNA at a dose of 1 mgikg (s.c.). At a dose of 5 mgikg (s.c.), CORT, but not ALDO, increased bFGF and NGF mRNA -1.5fold (data not shown).
In the hippocampus, the CORT-evoked changes in the expression of both NGF and bFGF mRNA followed a pattern similar to that observed after DEX. Thus, by 3 hr, the natural glucocorticoid elicited a 3-and 1.5fold increase in bFGF and NGF mRNA, respectively (Fig. 7B) . In contrast, ALDO failed to change NGF mRNA levels, and induced bFGF mRNA to an extent weaker than that observed after CORT (Fig. 7B) . March 15, 1996, 16(6) 
DISCUSSION
In addition to playing an important role in mediating stress responses, adrenal corticosteroids influence survival of specific neuronal populations (Sloviter et al., 1989; Gould et al., 1990) . We have used ACTH, naturally occurring adrenal steroids, and the synthetic glucocorticoid DEX to test the importance of these hormones in the induction of neurotrophic factor expression in rat brain. The data presented here demonstrate that ACTH, CORT, ALDO, and DEX increase brain levels of the mRNA for NGF and bFGF, two polypeptides that exert trophic activity on basal forebrain cholincrgic neurons (for review, see Mocchetti and Wrathall, 1995) , suggesting that the adrenal cortical system may influence neuronal plasticity.
The DEX-induced accumulation of NGF mRNA is temporally and anatomically distinct from that of bFGF mRNA. Whereas NGF mRNA induction peaks at 3 hr, that of bFGF peaks at 6 hr in most of the brain regions examined. Moreover, the DEXmediated induction of NGF mRNA is confined to the cerebral cortex and hippocampus, whereas bFGF mRNA increase occurs in several brain areas, suggesting that transcriptional activation and DNA-binding properties of NGF and bFGF promoters may respond differently to changes in hormone levels. Indeed, the results obtained by in situ hybridization show that the DEXmediated increase in NGF mRNA levels is localized in superficial layers of the cerebral cortex and in the dentate gyrus of the hippocampus, indicative of enhanced neuronal expression. Instead, the DEX-evoked accumulation of bFGF mRNA levels was localized in glial cells of the hippocampal stratum lacunosum moleculare, but not in layers of the hippocampus enriched in neurons such as CA1 and CA2. Furthermore, in the cerebral cortex, the glucocorticoid-mediated induction of bFGF mRNA is widespread and heterogeneous, consistent with the suggestion that bFGF expression is induced in glial cells. Thus, our data are in line with the notion that pharmacologically induced expression of the NGF gene in adult uninjured rat brain occurs primarily in neurons (Isackson et al., 1991; Hayes et al., 1995) and further support the suggestion that glial cells are able to express bFGF mRNA in response to noninjurious changes in synaptic activity (Hayes et al., 1995) .
It has been cstablishcd that DEX increases NGF protein in the cerebral cortex of developing and adult rats (Fabrazzo et al., 1991; Saporito et al., 1994) . The data presented here show that in the hippocampus, DEX also increases bFGF protein. The accumulation of bFGF protein temporally follows the increase in bFGF mRNA. In fact, a significant increase in bFGF protein levels was observed at 6 hr. A similar "delay" in protein induction after DEX has been observed for NGF in the cerebral cortex (Fabrazzo et al., 1991) , suggesting that accumulation of neurotrophic factor proteins is an event secondary to the activation of bFGF (or NGF) gene transcription or mRNA stabilization. Although a complete time-course study on the effect of DEX on bFGF protein has not been carried out, overall, our data indicate that stimulation of glucocorticoid receptors enhances the synthesis and availability of these trophic factors in selected regions of the adult rat CNS.
The exact mechanism by which adrenal steroids stimulate bFGF and NGF mRNA accumulation does not appear to be easily definable. Brain corticosteroid receptors are pharmacologically and anatomically distinct. Type I receptors have high affinity for both mineralcorticoids and glucocorticoids, and a three-to fivefold lower affinity for the synthetic glucocorticoid DEX (Beaumont and Fanestil, 1983; Reul and DeKloet, 198.5) . In contrast, type II receptors possess high affinity for DEX and a IO-to 20-fold lower affinity for ALDO (DeKloet et al., 1975; Krozowski and Funder 1983; Spencer et al., 1990) . Thus, DEX has been considered a type II receptor agonist. Moreover, regional studies on the density of these receptors have shown a contrasting variability, with type I being far more abundant in the hippocampus, and type II uniformly expressed throughout the brain (Fuxe et al., 1985; Reul and DeKloet, 1985; Chao et al., 1989) . In this study, we have provided several lines of evidence which demonstrate that glucocorticoids, and not mineralcorticoids, are the main corticosteroids regulating the expression of NGF and bFGF mRNA. First, the DEX-mediated increase in NGF and bFGF mRNA occurs in different brain areas, in accordance with the wider distribution of type II receptors. Second, CORT, but not ALDO, elicits an anatomical increase in NGF and bFGF mRNA expression similar in magnitude to that observed after DEX. Finally, in the hippocampus, an area rich in type I receptors, ALDO minimally increased bFGF expression and failed to change the expression of NGF mRNA. Thus, although we cannot definitively rule out a role for mineralcorticoids, it appears that expression of NGF and bFGF is predominantly under the control of glucocorticoids. Whether these neurotrophic factors are colocalized with cells expressing type II receptors is still unclear. Isotopic and colorimetric labeling will allow us to determine whether bFGF and NGF mRNA colocalize with type II receptors and whether the selective anatomical activation of these trophic factors is attributable to a direct control of glucocorticoids or to a transsynaptic mechanism evoked by DEX.
The dose of DEX used for these studies roughly mimics the concentration of blood corticosterone after excessive stress (Sapolsky et al., 1986) . Stress has been shown to affect expression of neurotrophins in the hippocampus (Smith et al., 1995) , indicating that the pituitary-adrenocortical axis is involved in the regulation of neurotrophic factor synthesis. Seizure-evoked stress can cause the rclcasc of ACTH and the conscqucnt rise in blood glucocorticoid concentration. On the other hand, seizure-evoked synaptic activity has been shown to increase the cxprcssion of NGF and bFGF in the hippocampus and cerebral cortex (Gall and Isackson, 1989; Riva et al., 1992; Follcsa ct al., 1994; Gall et al., 1994) , suggesting that trophic factor synthesis may require activation of neurotransmitter receptors. We have previously shown that the seizure-mediated accumulation of hippocampal NGF can be prevented in adrenalectomized rats without compromising the number and duration of seizure episodes (Mocchetti et al., 1991; Sun et al., 1993) , indicating that adrenal steroid hormones play an important role in mediating induction of NGF and bFGF mRNA evoked by seizure episodes. Our findings, by providing direct evidence that ACTH regulates the expression of bFGF and NGF mRNA in sham-operated but not in adrenalectomized rats, support the suggestion that some of the effects observed after excessive synaptic activity may be attributed to events linked to stress.
The present data, by establishing that ACTH, CORT, and DEX influence accumulation of NGF and bFGF mRNA, confirm the early hypothesis that glucocorticoids may regulate expression of neurotrophic factors in the adult CNS (Mocchctti, 1991) , and suggest that hormones may exert their effect on CNS homeostasis via the regulation of trophic factor activity. Thyroxine, for instance, administered to adult mice for 21 d, increases NGF concentration in the cerebral cortex, brainstem, and cerebellum (Walker et al., 1979) . Furthermore, in adult mice, intermale aggressive behavior elicited by social isolation for several days induces NGF expression in the magnocellular preoptic and ventrolateral nuclei of the hypothalamus (Spillantini et al., 1989; Aloe et al., 1990) , suggesting that NGF may be involved in the regulation of those hypothalamic functions that integrate sexual aggression with sex-related endocrine function. Several lines of independent investigations have shown that sex hormones may also play a role in the regulation of neurotrophic factors. Indeed, in the brain, estrogen receptors colocalize with neurotrophin receptors (Miranda et al., 1993) . In ovariectomized rats, BDNF mRNA levels decrease in the cerebral cortex (Singh et al., 1995) , and estrogen replacement causes a reduction of hippocampal NGF mRNA (Gibbs et al., 1994) . Our data have shown that in the hypothalamus DEX increases bFGF mRNA only. Thus, it appears that different classes of hormones may promote expression of different trophic factors in an anatomically specific manner.
Glucocorticoids induce bFGF and NGF biosynthesis. However, the physiological implication of this event remains to be determined. Although it is now unequivocal that bFGF and NGF play an important role during development of the CNS, their potential function in the adult CNS remain controversial. bFGF and NGF have been shown to protect hippocampal and cortical neurons against hypoglycemic damage (Cheng and Mattson, 1991) . Glucocorticoids, as in many peripheral tissues, inhibit glucose uptake and utilization in the brain (Sapolsky, 1987) , which may limit energy utilization.
Neurons are notoriously vulnerable to low energy. Therefore, activation of glucocorticoid receptors, by causing imbalance of glucose availability, may lead to potential neuronal damage. We propose that the increased availability of bFGF and NGF after glucocorticoids may occur as an event in response to potential neuronal damage caused by stress-induced hypoglycemia.
Our data have shown a defined temporal and regional pattern of induction of bFGF and NGF synthesis after DEX and CORT, suggesting that glucocorticoids may possess trophic activity. This hypothesis is supported by the finding that physiological conccntration of glucocorticoids is crucial for neuronal survival as adrcnalectomy acccleratcs degeneration of hippocampal neurons (Sloviter et al., 1989 
